通过过渡状态效应调节布鲁顿氨酸激酶抑制剂的结合动力学
Eduardo Bravo1, Yong Li1, David Yin-Wei Lin2
1Center for the Advanced Study of Drug Action, Department of Chemistry, Stony Brook University, Stony Brook, New York 11794-3400, United States.
Journal of the American Chemical Society
|July 29, 2025
概括
这项研究引入了一种基于知识的方法,用于设计具有受控结合动力学的布鲁顿氨酸激酶 (BTK) 抑制剂. 这项研究产生了具有延长停留时间的新型抑制剂,改善了B细胞恶性瘤和自身免疫性疾病的治疗潜力.
科学领域:
- 生物化学
- 医学化学
- 药理学
背景情况:
- 小分子的优化旨在提高目标有效性和选择性,同时最大限度地减少非目标效应.
- 工程动力选择性与热力学选择性一起,对于生物系统至关重要,但很难以理性的方式实现.
- 布鲁顿氨酸激酶 (BTK) 是治疗B细胞恶性瘤和自身免疫性疾病的关键点.
研究的目的:
- 开发一种系统的,基于知识的方法来设计BTK的调制结合动力学抑制剂.
- 研究抑制剂结构,BTK抑制剂相互作用和酶抑制的动力学之间的关系.
- 通过将动力参数从平衡亲和度解开来设计具有延长停留时间的BTK抑制剂.
主要方法:
- 对现有的BTK抑制剂进行详细的动力学评估.
- 结构研究以阐明控制抑制动学的BTK抑制剂相互作用.
- 针对酶背口的R脊相互作用的基于pyrazolopyrimidine的抑制剂的设计和合成.
- 对抑制剂结合动力学 (k_on,k_off) 和平衡 afinity 的评估.
主要成果:
- 确定影响结合动学的关键BTK抑制剂相互作用.
- 成功设计了调节过渡状态稳定性的pyrazolopyrimidine抑制剂.
- 开发出具有显著延长停留时间的BTK抑制剂.
- 证明动力参数 (k_on,k_off) 可以独立于平衡亲和度进行调制.
结论:
- 一种系统的方法可以合理设计具有特定动力特征的抑制剂.
- 调节与R脊柱的相互作用是设计抑制剂停留时间的可行策略.
- 开发的具有延长停留时间的BTK抑制剂有可能改善B细胞恶性瘤和自身免疫性疾病的治疗结果.
相关概念视频
01:16Protein-Drug Binding: Mechanism and Kinetics
954
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
954
01:58Cooperative Allosteric Transitions
2.4K
2.4K
01:26Receptor Tyrosine Kinases
14.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
14.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
02:18The Equilibrium Binding Constant and Binding Strength
13.5K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.5K
00:49Ligand Binding and Linkage
4.9K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.9K